Crescendo Biologics Raises $28M To Develop Fully Human Antibody-Fragment Technology
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.K. biotech aims to transform the biologics market with its first-in-class human antibody-fragment technology, with mild to moderate psoriasis the lead therapeutic target.